Cite this: *Chem. Commun.*, 2020, 56, 5496

Received 16th January 2020,
Accepted 5th March 2020

DOI: 10.1039/d0cc00444h

rsc.li/chemcomm

Consecutive 5'- and 3'-amide linkages stabilise antisense oligonucleotides and elicit an efficient RNase H response†

Sven Epple,^{id}^a Cameron Thorpe,^{id}^a Ysobel R. Baker,^{id}^a Afaf H. El-Sagheer^{id}^{ab} and Tom Brown^{id}^{*a}

Antisense oligonucleotides are now entering the clinic for hard-to-treat diseases. New chemical modifications are urgently required to enhance their drug-like properties. We combine amide coupling with standard oligonucleotide synthesis to assemble backbone chimera gapmers that trigger an efficient RNase H response while improving serum life time and cellular uptake.

Antisense oligonucleotides (ASOs) are short (~20mer) chemically modified oligomers that bind to their complementary RNA targets to modulate gene expression at the mRNA level.^{1,2} Thus, ASOs can target proteins that are considered undruggable through conventional approaches.³ As such, they hold enormous promise for hard-to-treat diseases as evidenced by a number of recently approved oligonucleotide (ON)-based drugs.^{4–6}

Chemical modifications are essential to improve the serum stability and pharmacodynamic properties of ASOs, as unmodified ONs are rapidly digested by nucleases *in vivo*^{7,8} and suffer from poor cellular uptake and tissue distribution.⁹ Whilst there have been considerable advances to modify ONs either at the nucleobase, sugar or backbone, a set of distinct chemical modifications to confer ideal drug-like properties has not yet been achieved.¹⁰ Commonly used ribose modifications include 2'-F, 2'-OMe, 2'-O-(2-methoxyethyl) and locked nucleic acids, all of which have been shown to improve target affinity and serum stability.¹¹ The most commonly used phosphodiester (PO) mimic is the phosphorothioate (PS) linkage which is compatible with ribonuclease H (RNase H) activation,¹² a mechanism resulting in degradation of an mRNA upon formation of an ASO:mRNA heteroduplex. PS linkages also improve metabolic stability¹³ and enhance pharmacodynamic properties through interactions with plasma proteins.^{8,14,15} However, unspecific protein binding can contribute to the toxic

potential of PS-ASOs^{16,17} and the PS linkage is *P*-chiral resulting in a mixture of diastereomers (more than half a million isomers in Mipomersen^{12,18}). Moreover, inefficient cellular uptake remains a major challenge for ASO therapeutics. Therefore, the investigation of other artificial backbone linkages is urgently needed.

Charge-neutral backbone modifications represent an interesting class of PO mimics. Among those, (thio)phosphonoacetate esters,¹⁹ phosphotriesters²⁰ and alkyl phosphonates²¹ can enhance cellular uptake by eliminating the PO negative charges. Moreover, incorporation of a single methylphosphonate can eliminate hepatotoxicity of PS-ASOs.²² Phosphorodiamidate morpholino oligomers (PMOs) combine backbone and sugar modifications and enhance delivery through interactions with scavenger receptors,²³ but are not compatible with standard ON synthesis. All aforementioned PO mimics also suffer from increased steric complexity due to their *P*-chiral linkages.

The absence of a chiral centre and the well-established solid-phase peptide synthesis methods make the amide internucleoside linkage²⁴ (AM, Fig. 1A) a promising candidate for backbone surrogates. Within DNA, isolated amides can slightly increase duplex stability with target RNA²⁴ while consecutive amides were reported to have minimal effects.²⁵ Amide-modified ONs are stable in serum²⁴ and the backbone is well tolerated in replication, transcription²⁶ and RNAi²⁷ but its application in the context of RNase H activation has not been reported.

Here we report the introduction of isolated and consecutive amide linkages into ONs for RNase H-based antisense applications. We discuss possible ASO designs that contain the AM backbone to induce RNA target degradation and we evaluate serum stability and cellular uptake of a partially uncharged AM-gapmer ON.

Isolated AM internucleoside linkages were introduced *via* dinucleotide phosphoramidite **6** (Fig. 1A) with an internal amide as the building block for standard ON synthesis. Preparation of phosphoramidite **6** required 5'-tritylation of monomer **1**²⁵ followed by ester hydrolysis to obtain acid **3**. Amide coupling with amine **4**²⁸ resulted in dimer **5** and subsequent phosphitylation gave **6** which can be used in standard ON synthesis.²⁴ Phosphoramidite **6** was then used to synthesise ASOs (ON2, ON4, ON5, Fig. 1B)

^a Chemistry Research Laboratory, University of Oxford, Oxford, OX1 3TA, UK.

E-mail: tom.brown@chem.ox.ac.uk

^b Chemistry Branch, Department of Science and Mathematics, Faculty of Petroleum and Mining Engineering, Suez University, Suez 43721, Egypt

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0cc00444h

AM-PO chimeras with sections of consecutive AM linkages were synthesised by adapting published protocols (Fig. 2).^{25,30–32} AM-coupling (i) of acid 7²⁵ to a 5'-amine forms the AM bond and deprotection (ii) and successive AM-coupling (i) of monomer 7 builds up sections of nucleosides consecutively linked through the AM linkage (AM-cycle). Introduction of a 5'-OH was achieved by AM-coupling (i) of monomer 3 and subsequent deprotection (ii). ON synthesis using standard phosphoramidite monomers builds up sections with PO linkages (PO-cycle). Transition from the PO-cycle to the AM-cycle can be achieved by PO-coupling (iii) of commercially available phosphoramidite 8 followed by oxidation (iv) and detritylation (ii) to introduce a 5'-amine as a substrate for

The consecutive AM backbones in ON6 constitute the flanking wings of the ASO, a commonly used strategy to retain RNase H activity while utilising the properties of otherwise RNase H-incompatible modifications, including the 2'-OMe modification³³ (ON3, Fig. 1B). However, this strategy has not yet been reported for

Fig. 3 (A and D) Reversed-phase ultra performance liquid chromatography (RP-UPLC) traces of crude ONs. (B and E) RP-UPLC traces of purified ONs. (C and F) Mass analysis. ON6: 5'-T_AT_AT_AT_AT_PC_PC_PT_PG_PA_PT_PG_PT_AT_AT_AT-3'; ON9: 5'-F_LP_AT_AT_AT_AT_PC_PC_PT_PG_PA_PT_PG_PT_AT_AT_AT-3'. *Peak corresponding to desired ON. For full traces see Fig. S1 and S2 (ESI†).

Fig. 4 Degradation of FL-RNA2 by RNase H after incubation with ASOs at 37 °C over time. ASOs are ON6–ON8. ASO/FL-RNA2, 1/4 (mole/mole). Time points are 0 min, 1 min, 5 min, 15 min, 30 min and 1 h. Quantification of full-length FL-RNA2 was performed from gels using ImageJ. $n = 3 \pm$ standard error of the mean. FL-RNA2: 5'-FL-AAAAACUAUCAGGAAAAA-3'. Full gel images are shown in Fig. S3 (ESI†). For sequences see Table 1.

AM backbones. Thus, ON6 was tested in the RNase H assay while ON7 and ON8 (Fig. 4 and Table 1) were used as positive controls to induce degradation of a 5'-FL-labelled complementary target RNA (FL-RNA2). Aliquots of the reaction buffers containing *E. coli* RNase H, FL-RNA2 and a catalytic amount of ASOs (ON6, ON7 or ON8) were quenched at different time points and analysed by gel electrophoresis (Fig. 4 and Fig. S3, ESI†). The gels show that all tested ASOs induce complete target degradation within 30 min at 37 °C. Quantification confirmed that AM-gapmer ON6 activates RNase H as efficiently as the controls ON7 and ON8. This is a clear improvement on previously reported gapmers with charge-neutral wings using peptide nucleic acids (PNAs) which only induce target degradation in a non-catalytic way.³⁴ Watts *et al.* reported that improved gapmer designs and optimisation of linkers between PNA and DNA sections can lead to catalytic activity but the charge-neutral section was limited to only one wing.³⁵ In comparison, AM-gapmer ON6 shows efficient catalytic degradation of the target RNA.

No correlation was observed between the cleavage rate of an RNA target by RNase H with ON6–8 and the measured melting temperatures (T_m s, Table 1 and Fig. S4, ESI†). The 2'-OMe modifications in gapmer ON7 increased target affinity to RNA by +2.5 °C (+0.25 °C per modification (mod)) whereas the amide backbone in ON6 slightly decreased duplex stability with RNA by −1.5 °C (−0.19 °C per mod) compared to unmodified ON8. This is consistent with the literature for both modifications.^{11,25}

A flexible 4'-endo sugar pucker, a rigid sugar phosphate backbone, and a duplex conformation between A and B are essential for an efficient RNase H response.³⁶ In this context, we investigated the structural changes in duplexes induced by the

AM backbone. We did not observe significant perturbation of the duplex structures formed by ON6 with DNA or RNA targets when compared to ON8 (an unmodified DNA ON) in circular dichroism experiments (Fig. S5, ESI†), which is consistent with the high efficiency of ON6 in inducing an RNase H response.

Enzymatic stability of ASOs is important to ensure optimal biological half-life and therapeutic efficacy. The terminal amides in ON6 result in enhanced nuclease resistance and longer serum lifetime in foetal bovine serum (FBS) compared to ON7 and ON8 which were both rapidly degraded (Fig. S6, ESI†). As previously reported,³⁷ the 2'-OMe modifications in ON7 slightly extend serum lifetime but are not as effective as the amide bonds in ON6.

Potential enhanced cellular uptake of the AM-gapmer design was evaluated by confocal laser scanning microscopy (CLSM). For this experiment, ON6 was fluorescently labelled at the 5'-end to give ON9 (Fig. 3D–F) in which eight PO linkages were replaced by charge-neutral AM bonds and the ON has a charge-to-linkage ratio of 0.56 (including the PO linkage between FL and the 5'-end). No solubility issues were encountered with this oligomer. ON10 and ON11 represent the fluorescently labelled derivatives of ON7 and ON8 respectively in which all 17 internucleoside linkages consist of negatively charged PO bonds, with an additional PO bond for the attachment of FL (Fig. 5). HeLa cells were incubated with 5 μM ON9–ON11 in serum-free medium and analysed by CLSM after fixation. AM-gapmer ON9 showed increased intracellular accumulation compared to ON10 and ON11 for which a distinct fluorescent signal inside the cell was absent (Fig. 5 and Fig. S7 for a general view, ESI†). The localised fluorescent signals observed for ON9 (Fig. 5A) suggest that the uptake mechanism leads to its partial entrapment within subcellular compartments. Co-incubation of ON9 with fluorescently tagged epidermal growth factor (EGF) shows that only a low number of FL signals were co-localised with stained endosomes (Fig. S8, ESI†). Moreover, a clear increase of punctuated fluorescence for ON9 was only detected after incubation for 16 h while receptor-mediated endocytosis is known to happen within <30 min. Together, our preliminary results suggest that ON uptake may be occurring through fluid phase endocytosis which results in unspecific uptake from the extracellular fluid into vacuoles, while their fate upon maturation can be highly variable.³⁸ These observations are also in agreement with reports that fully charge-neutral methyl phosphonate-modified ASOs enter the cell *via* fluid phase endocytosis after 10–12 hours of incubation.²¹ Similar results showed enhanced cellular uptake of ASOs in which half the charge was neutralised by phosphotriesters.¹⁹

Table 1 T_m s of AM-gapmer ON6 and 2'-OMe-gapmer ON7 compared to unmodified DNA ON8 against a complementary RNA and DNA target. Values were obtained from the maxima dA_{260} vs. T for 3 mM of each ON in 10 mM phosphate buffer, 200 mM NaCl, pH 7.0, $n = 2 \pm$ SD. ΔT_m are relative to the unmodified control ON8

ON	(5' → 3')	RNA target		DNA target	
		T_m	ΔT_m	T_m	ΔT_m
ON6	T _a T _a T _a T _a T _p C _p C _p T _p G _p A _p T _p A _p G _p T _a T _a T _a T _a T	54.6	−1.5	52.3	−3.2
ON7	U _p U _p U _p U _p U _p C _p C _p T _p G _p A _p T _p A _p G _p U _p U _p U _p U _p U	58.6	+2.5	47.8	−7.7
ON8	T _p T _p T _p T _p T _p C _p C _p T _p G _p A _p T _p A _p G _p T _p T _p T _p T _p T	56.1	—	55.5	—

a = AM, p = PO, U = 2'-OMe uridine.

Fig. 5 HeLa cells were incubated with 5 μ M ON9–ON11 in serum-free medium for 16 h at 37 $^{\circ}$ C. Cells were fixed and nuclei stained with 4',6-diamidino-2-phenylindole (DAPI) before CLSM analysis. Scale bar: 25 μ m. ON9: 5'-FL_pT_aT_aT_aT_aT_pC_pC_pT_pG_pA_pT_pA_pG_pT_aT_aT_aT-3'; ON10: 5'-FL_pU_pU_pU_pU_pU_pC_pC_pT_pG_pA_pT_pA_pG_pU_pU_pU_pU_pU-3'; ON11: 5'-FL_pT_pT_pT_pC_pC_pT_pG_pA_pT_pA_pG_pT_pT_pT_pT-3'.

In conclusion, different ON chemistries and their effect on pharmacodynamics, pharmacokinetics, cellular delivery and toxicity are poorly understood and backbone modifications have been mainly focused on the PS linkage, leaving other chemistries underexplored. The recently reported applications of charge-neutral backbones to enhance cellular uptake^{19–21} and mediate toxicity²² emphasise the importance of exploring other artificial backbone structures. Here we report the partial replacement of the natural ON PO backbone by an amide internucleoside linkage and its effects on antisense activity, target engagement, serum stability and cellular uptake. We show that the AM linkage is well tolerated in the wings of an ASO gapmer design while retaining an efficient RNase H response. The stability of the formed duplex is only slightly decreased (-0.19 $^{\circ}$ C per mod) compared to unmodified DNA, and this does not compromise target engagement and RNA cleavage efficiency. The ease of chimeric gapmer design and synthesis with reduced steric complexity, retained catalytic efficiency, high serum stability and potentially enhanced cellular uptake all add desirable drug-like properties. Thus, the AM backbone mimic represents a valuable candidate for further development.

S. E. thanks EPSRC SBMCDT (EP/L015838/1) for a studentship, C. T. is supported by BBSRC grant BB/M011224/1, A. H. E.-S. by BBSRC grant BB/R008655/1 and YB by BBSRC grant BB/S018794/1.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 S. T. Crooke, *Nucleic Acid Ther.*, 2017, **27**, 70–77.
- 2 C. I. E. Smith and R. Zain, *Annu. Rev. Pharmacol. Toxicol.*, 2019, **59**, 605–630.
- 3 A. Khvorova and J. K. Watts, *Nat. Biotechnol.*, 2017, **35**, 238–248.
- 4 C. F. Bennett, *Annu. Rev. Med.*, 2019, **70**, 307–321.

- 5 S. J. Keam, *Drugs*, 2018, **78**, 1371–1376.
- 6 S. M. Hoy, *Drugs*, 2018, **78**, 1625–1631.
- 7 C. Rinaldi and M. J. A. Wood, *Nat. Rev. Neurol.*, 2017, **14**, 9–21.
- 8 R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan and A. A. Levin, *J. Pharmacol. Exp. Ther.*, 2001, **296**, 890–897.
- 9 R. S. Geary, D. Norris, R. Yu and C. F. Bennett, *Adv. Drug Delivery Rev.*, 2015, **87**, 46–51.
- 10 W. Brad Wan and P. P. Seth, *J. Med. Chem.*, 2016, **59**, 9645–9667.
- 11 S. Freier and K.-H. Altmann, *Nucleic Acids Res.*, 1997, **25**, 4429–4443.
- 12 N. Iwamoto, D. C. D. Butler, N. Svrikapa, S. Mohapatra, I. Zlatev, D. W. Y. Sah, Meena, S. M. Standley, G. Lu, L. H. Apponi, M. Frank-Kamenetsky, J. J. Zhang, C. Vargeese and G. L. Verdine, *Nat. Biotechnol.*, 2017, **35**, 845–851.
- 13 J. M. Campbell, T. A. Bacon and E. Wickstrom, *J. Biochem. Biophys. Methods*, 1990, **20**, 259–267.
- 14 T. A. Watanabe, R. S. Geary and A. A. Levin, *Oligonucleotides*, 2006, **16**, 169–180.
- 15 H. J. Gaus, R. Gupta, A. E. Chappell, M. E. Østergaard, E. E. Swayze and P. P. Seth, *Nucleic Acids Res.*, 2019, **47**, 1110–1122.
- 16 X. H. Liang, H. Sun, W. Shen and S. T. Crooke, *Nucleic Acids Res.*, 2015, **43**, 2927–2945.
- 17 T. A. Vickers, M. Rahdar, T. P. Prakash and S. T. Crooke, *Nucleic Acids Res.*, 2019, **47**, 10865–10880.
- 18 S. T. Crooke and R. S. Geary, *Br. J. Clin. Pharmacol.*, 2013, **76**, 269–276.
- 19 D. Sheehan, B. Lunstad, C. M. Yamada, B. G. Stell, M. H. Caruthers and D. J. Dellinger, *Nucleic Acids Res.*, 2003, **31**, 4109–4118.
- 20 B. R. Meade, K. Gogoi, A. S. Hamil, C. Palm-Apergi, A. Van Den Berg, J. C. Hagopian, A. D. Springer, A. Eguchi, A. D. Kacsinta, C. F. Dowdy, A. Presente, P. Lönn, M. Kaulich, N. Yoshioka, E. Gros, X. S. Cui and S. F. Dowdy, *Nat. Biotechnol.*, 2014, **32**, 1256–1261.
- 21 Y. Shoji, S. Akhtar, A. Periasamy, B. Herman and R. L. Juliano, *Nucleic Acids Res.*, 1991, **19**, 5543–5550.
- 22 M. T. Migawa, W. Shen, W. B. Wan, G. Vasquez, M. E. Østergaard, A. Low, C. L. De Hoyos, R. Gupta, S. Murray, M. Tanowitz, M. Bell, J. G. Nichols, H. Gaus, X. Liang, E. E. Swayze, S. T. Crooke and P. P. Seth, *Nucleic Acids Res.*, 2019, **47**, 5465–5479.
- 23 S. Miyatake, Y. Mizobe, M. K. Tsoumpra, K. R. Q. Lim, Y. Hara, F. Shabanpour, T. Yokota, S. Takeda and Y. Aoki, *Mol. Ther. – Nucleic Acids*, 2019, **14**, 520–535.
- 24 A. De Mesmaeker, A. Waldner, J. Lebreton, P. Hoffmann, V. Fritsch, R. M. Wolf and S. M. Freier, *Angew. Chem., Int. Ed. Engl.*, 1994, **33**, 226–229.
- 25 P. von Matt, A. De Mesmaeker, U. Piesles, W. Zürcher and K. H. Altmann, *Tetrahedron Lett.*, 1999, **40**, 2899–2902.
- 26 A. Shivalingam, A. E. S. Tyburn, A. H. El-Sagheer and T. Brown, *J. Am. Chem. Soc.*, 2017, **139**, 1575–1583.
- 27 D. Mutisya, T. Hardcastle, S. K. Cheruiyot, P. S. Pallan, S. D. Kennedy, M. Egli, M. L. Kelley, A. van, B. Smith and E. Rozners, *Nucleic Acids Res.*, 2017, **45**, 8142–8155.
- 28 I. Van Daele, H. Munier-Lehmann, M. Froeyen, J. Balzarini and S. Van Calenbergh, *J. Med. Chem.*, 2007, **50**, 5281–5292.
- 29 M. Nowotny, S. A. Gaidamakov, R. Ghirlando, S. M. Cerritelli, R. J. Crouch and W. Yang, *Mol. Cell*, 2007, **28**, 264–276.
- 30 B. M. Brandsen, A. R. Hesser, M. A. Castner, M. Chandra and S. K. Silverman, *J. Am. Chem. Soc.*, 2013, **135**, 16014–16017.
- 31 P. Tanui, S. D. Kennedy, B. D. Lunstad, A. Haas, D. Leake and E. Rozners, *Org. Biomol. Chem.*, 2014, **12**, 1207–1210.
- 32 V. Kotikam, J. A. Viel and E. Rozners, *Chem. – Eur. J.*, 2020, **26**, 685–690.
- 33 B. P. Monia, E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinasso, A. M. Kawasaki, P. D. Cook and S. M. Freier, *J. Biol. Chem.*, 1993, **268**, 14514–14522.
- 34 C. Malchère, J. Verheijen, S. Van der Laan, L. Bastide, J. Van Boom, B. Lebleu and I. Robbins, *Antisense Nucleic Acid Drug Dev.*, 2011, **10**, 463–468.
- 35 A. J. Debacker, V. K. Sharma, P. Meda Krishnamurthy, D. O'Reilly, R. Greenhill and J. K. Watts, *Biochemistry*, 2019, **58**, 582–589.
- 36 W. F. Lima, J. G. Nichols, H. Wu, T. P. Prakash, M. T. Migawa, T. K. Wyrzykiewicz, B. Bhat and S. T. Crooke, *J. Biol. Chem.*, 2004, **279**, 36317–36326.
- 37 P. Martin, *Helv. Chim. Acta*, 1995, **78**, 486–504.
- 38 J. P. Lim and P. A. Gleeson, *Immunol. Cell Biol.*, 2011, **89**, 836–843.